COSMO Pharmaceuticals SA
Research COSMO Pharmaceuticals SA (0RGI) on Bullrun: P/E 44.2, dividend yield 3.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker0RGI
- ExchangeLSE
- CountryIreland
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyGBP
- P/E44.2
- Dividend yield3.4%
- Financial periodFY2025
- RevenueEUR 104.17M
- Revenue growth-61.0%
- Net income-EUR 3.61M
- Free cash flow-EUR 17.95M
- Gross margin48.5%
Valuation Snapshot
P/E is 44.2; dividend yield is 3.4%.
Peer valuation comparison
Latest P/E is 44.2x versus a Healthcare sector median of 24.46x (80.7% above).
Latest dividend yield is 3.35% versus a Healthcare sector median of 2.11% (58.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 104.17M | -EUR 3.61M | -EUR 17.95M | 48.5% | n/a | EUR 55.87M | EUR 4.27M | EUR 482.30M |
| FY2024 | EUR 266.79M | EUR 133.24M | EUR 156.76M | 83.0% | 8.12 | EUR 44.30M | EUR 2.20M | EUR 498.33M |
| FY2023 | EUR 92.78M | -EUR 10.78M | EUR 18.31M | 79.4% | -0.67 | EUR 50.28M | EUR 1.84M | EUR 396.82M |
| FY2022 | EUR 102.09M | EUR 17.23M | EUR 25.92M | 81.6% | 1.05 | EUR 185.83M | EUR 173.60M | EUR 456.93M |
| FY2021 | n/a | n/a | n/a | n/a | 1.28 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-26 | n/a | 44.2 | n/a | 2.1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.1 GBP, yield 3.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.76 EUR |
| FY2024 | 1.78 EUR |
| FY2023 | 0.93 EUR |
| FY2022 | 0.9 EUR |
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is COSMO Pharmaceuticals SA's P/E ratio?
COSMO Pharmaceuticals SA's price-to-earnings (P/E) ratio is 44.2.
Does COSMO Pharmaceuticals SA pay a dividend?
COSMO Pharmaceuticals SA has a dividend yield of 3.4%.
What does COSMO Pharmaceuticals SA do?
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.